Stockreport

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Emergent BioSolutions Inc.  (EBS) 
Last emergent biosolutions inc. earnings: 4/30 04:08 pm Check Earnings Report
US:NYSE Investor Relations: investors.emergentbiosolutions.com
PDF GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Na [Read more]